MedImmune Ventures leads Series A round for G1 Therapeutics
G1 Therapeutics said Wednesday that it has closed $12.5 million in Series A financing. MedImmune Ventures led the round with participation from Hatteras Venture Partners and Mountain Group Capital. Also, Dr. Michael Gutch, managing director at MedImmune Ventures and Dr. Ron Laufer, senior managing director at MedImmune Ventures, have joined G1's board of directors. Based in Chapel Hill, NC, G1 is a pharmaceutical company focused on cancer therapy and biodefense applications.
16 October 2013•3 mins read
